Pharmacokinetics and pharmacodynamics of the endothelin‐receptor antagonist bosentan in healthy human subjects

@article{Weber1996PharmacokineticsAP,
  title={Pharmacokinetics and pharmacodynamics of the endothelin‐receptor antagonist bosentan in healthy human subjects},
  author={Cornelia Weber and Rita Schmitt and Herbert Birnboeck and G{\'e}rard Hopfgartner and Sjoerd P. Marle and Pierre A. M. Peeters and Jan H. G. Jonkman and Charles‐Richard Jones},
  journal={Clinical Pharmacology \& Therapeutics},
  year={1996},
  volume={60}
}
View on Wiley
ncbi.nlm.nih.gov
202 Citations
Highly Influential Citations
8
Background Citations
54
Methods Citations
12
Results Citations
12

202 Citations

Citation Type

Citation Type

Pharmacokinetics and pharmacodynamics of SB 209670, an endothelin receptor antagonist: Effects on the regulation of renal vascular tone
In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide
In a clinical trial with patients with chronic heart failure, a higher incidence ofelevated levels of liver transaminases was observed during concomitant treatment with bosentan, a dual endothelin…
Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension
The pharmacology of bosentan.
TLDR
Bosentan is a combined and competitive antagonist of both ETA and ETB receptors that is selective for the endothelin system that potently antagonises the vascular response elicited by the endothelins in vitro and in vivo.
La pharmacologie de l'endothéline et de son antagoniste bosentan
TLDR
Preclinical and clinical data suggest that bosentan might become a new approach for the chronic treatment of these cadiovascular and pulmonary diseases.
Endothelin Ligands and their Experimental Effects Within the Human Circulation
TLDR
A number of endothelin (ET) receptor antagonists have been developed as research tools and as potential medicines and several are at various stages of clinical evaluation.
Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans.
TLDR
The data suggest that ABT-627 may be a valuable tool in treatment of cardiovascular disease because it is well tolerated, rapidly absorbed, effectively blocks ET-1 induced vasoconstriction and causes a decrease in total peripheral resistance and mean arterial pressure.
Dual ETA/ETB vs. selective ETA endothelin receptor antagonism in patients with pulmonary hypertension
TLDR
To answer the question of whether selective or dual ETRA is preferable in patients with PAH, experimental and clinical data with relevance to the pulmonary circulation are reviewed in this article.
Protection against aspirin‐induced human gastric mucosal injury by bosentan, a new endothelin‐1 receptor antagonist
  • Duggan, Stack, Hawkey
  • Medicine, Biology
    Alimentary pharmacology & therapeutics
  • 1999
TLDR
Gastric ulceration induced by aspirin and by non‐steroidal anti‐inflammatory drugs (NSAIDs) is a major clinical problem and there is evidence that NSAID‐induced injury may cause endothelin activation.
Single‐Dose Pharmacokinetics of Atrasentan, an Endothelin‐A Receptor Antagonist
TLDR
Atrasentan pharmacokinetics was linear in the 1 to 23.25 mg dose range, with some dose dependency in the highest dose group, and the apparent volume of distribution was large, consistent with extensive tissue distribution.
...
...

References

SHOWING 1-10 OF 33 REFERENCES
The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasm.
TLDR
In the dogs treated with bosentan, theBA spasm on Day 7 was significantly ameliorated compared with the BA spasm in the untreated dogs, which might indicate whether or not ET is involved in the pathogenesis of cerebral vasospasm.
Pharmacologic target‐mediated drug disposition
  • G. Levy
  • Biology, Psychology
    Clinical pharmacology and therapeutics
  • 1994
Clinical Pharmacology and Therapeutics (1994) 56, 248–252; doi:10.1038/clpt.1994.134
Effect of different endothelin receptor antagonists and of the novel non‐peptide antagonist Ro 46‐2005 on endothelin levels in rat plasma
Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.
TLDR
Bosentan is the most potent orally active antagonist of ET receptors described so far and its pharmacological profile makes bosentan a potentially useful drug in the management of clinical disorders associated with vasoconstriction.
The activity of peptides of the endothelin family in various mammalian smooth muscle preparations.
A case of bleeding requiring hospitalization that was likely caused by an interaction between warfarin and levamisole
Novel receptor antagonists welcome a new era in endothelin biology.
Endothelin receptor antagonists inhibit endothelin in human skin microcirculation.
TLDR
Endothelin is a potent vasoconstrictor peptide produced by endothelial cells, but its role in physiology and disease is uncertain and a double injection model was developed, allowing simultaneous injection of two substances.
Clearance of circulating endothelin-1 by ETB receptors in rats.
TLDR
It is suggested that ETB receptors play an important role in the clearance of ET-1, as about 80% of bolus-injected [125I]ET-1 was retained by the lungs after one passage.
Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan).
TLDR
Endothelin plays a role in the maintenance of blood pressure in CHF rats, as evidenced by the significant reduction in mean arterial pressure after oral administration of bosentan, and endothelin antagonists may be useful therapeutic agents in the treatment of CHF.
...
...